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LETTERS TO THE EDITOR
Immunologic Protection Afforded by Sunscreens Beyond
Designated Sun Protection Factors?
To the Editor:
In the June issue of the Journal of Investigative Dermatology, Davenport et al
(1997) reported on the capacity of various sunscreens to protect against
ultraviolet radiation (UVR)-induced suppression of the alloantigen-
presenting activity of epidermal cells. They used a system in which
human skin explants were exposed in culture to graded doses of solar
simulated UVR, and epidermal cells were then isolated and used as
stimulators in a mixed epidermal cell-leukocyte reaction. Five different
sunscreens with sun protection factors (SPF) ranging from 3.5 to 5.7
afforded full immune protection up to 8 minimal erythema dose
(MED) equivalents of UVR. The results of this study are important
because of the controversy surrounding the potential of sunscreens to
provide immune protection (Bestak et al, 1995; Granstein, 1995;
Roberts and Beasley, 1995; Whitemore and Morison, 1995; Wolf and
Kripke, 1996; Walker and Young, 1997) and the need to develop a
relevant, standardized test for assessing the immune protective capacity
of sunscreens. Unfortunately, however, the authors did not determine
immune protection factors for the sunscreens and therefore concluded
incorrectly that all the sunscreens protected epidermal alloantigen-
presenting function beyond their SPF value.
The conventional mode of SPF determination is to divide the
minimum UV dose eliciting a detectable response in sunscreen-
protected skin by the minimum dose eliciting a response in unprotected
skin. In this study, a minimum immunosuppressive dose (MISD)
was not determined, which would have allowed calculation of an
immunosuppression protection factor (IPF) based on a minimally
effective UV dose. None the less, the data presented in Fig 3 and
Table I of the paper permit estimation of the dose required for 50%
immune suppression (ISD50), which has been used in other studies
(Roberts and Beasley, 1995) to derive an IPF. Dividing the ISD50
obtained with sunscreens by the ISD50 obtained without sunscreens
reveals that, measured in this way, the IPF are only around 2.4. Thus,
the conclusion that ‘‘sunscreen agents all protect epidermal alloantigen-
presenting function beyond their designated SPF values’’ (Davenport
et al, 1997) is incorrect.
In spite of the erroneous conclusion, this model represents an
important advance in that it employs human, rather than murine, skin,
a light source that approximates the UV content of natural sunlight,
and a range of UV doses, rather than a single dose. It also serves to
illustrate the difficulties inherent in attempting to relate a sunscreen’s
IPF to its SPF. One way would be to ask whether a sunscreen with a
particular SPF will protect against both immune suppression and
erythema at a given dose of solar UVR, which seems to be the
approach taken by Davenport et al (1997). The problem with this
approach is that the IPF and SPF both depend critically on their
respective action spectra, and although that for erythema is well
defined, there is little information on action spectra for the various
measures of immune suppression in humans. A second problem is that
the relationship between MED and MISD is likely to differ greatly in
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different individuals. An individual’s MED depends heavily on skin
type; in contrast, there appears to be little correlation between skin
type and MISD, based on in vivo measurement of the contact
hypersensitivity response (Vermeer et al, 1991). Similarly, exposing
human subjects to 1.25 MED of solar simulated UV produced a large
variation in depletion of epidermal Langerhans cells (0–64%) 24 h
later, and no correlation was found between MED and depletion of
Langerhans cells in individuals (Alcalay et al, 1989). As Davenport et al
(1997) point out, sensitivity to UV-induced immune suppression seems
to be under genetic control; however, the relevant genes appear to be
independent of those controlling skin type (Streilein et al, 1994). Thus,
MED and MISD are independent variables whose relationship in a
particular individual is completely unpredictable. Therefore, the most
objective approach for assessing a sunscreen’s immunoprotective capa-
city is to determine an MISD or ISD50 for the particular immunologic
assay and to calculate an IPF using the conventional formula.
Clearly, more information is needed on the variance of MISD
among individuals, the action spectra for various forms of immune
suppression, how the in vitro alloantigen presentation assay relates to
an immune response in vivo, and whether the MISD from in vitro
irradiation reflects the MISD obtained following in vivo irradiation.
Although the study by Davenport et al (1997) represents an important
step in developing an in vitro assay for immune protection, much remains
to be done before the significance of this assay for photoprotection of
humans in vivo becomes clear.
Peter Wolf
Department of Dermatology, Karl Franzens University, Graz, Austria
Margaret L. Kripke
The University of Texas, M.D. Anderson Cancer Center, Houston,
Texas, U.S.A.
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